Abstract
Background. Vitamin D3 as a multifunctional biological agent actively participates in the pathogenesis of diabetic retinopathy (DR) in type 2 diabetes mellitus (T2DM), which allows researchers to consider it a potential biomarker for assessing patient status. We aimed to examine plasma vitamin D3 concentrations in patients with DR associated with T2DM and to analyze their correlations with parameters of inflammation, lipid metabolism, and neurodegeneration to identify new biomarkers. Materials and methods. We enrolled 106 patients (106 eyes) diagnosed with DR on the background of T2DM and divided them into subgroups according to the ETDRS severity scale. The study design included 3 groups: patients with non-proli­ferative DR (level 47–53e), moderate proliferative DR (level 61–75), and advanced proliferative DR (level 81–85). The control group included 64 relatively healthy individuals matched by age and sex. Plasma concentrations of vitamin D3, interleukin (IL) 1β, IL-10, ferritin, homocysteine, and non-neuronal enolase (NNE) were measured using enzyme-linked immunosorbent assay, and lipid profiles were analyzed. Statistical analysis was performed using IBM SPSS Statistics 23 and MedStat programs. Results. Patients with DR and vitamin D3 deficiency on the background of T2DM showed clear signs of chronic systemic inflammation and a relationship with NNE concentration, indicating more pronounced low-grade microglial inflammation in the brain and retina, a key mechanism underlying neurodegeneration and associated vision loss. This cohort also had a significant correlation between ferritin and IL-10 levels, but not IL-1β, which supports a differentiated approach to monitoring chronic systemic inflammation. Patients with advanced proliferative DR demonstrated significantly lower vitamin D3 levels if they were not receiving statin therapy. Conclusions. Plasma vitamin D3 concentration in patients with DR associated with T2DM serves as a biomarker for assessing neurodegeneration, systemic inflammation, and clinical outcomes, providing a basis for individualized patient management and DR prognosis. Statin therapy helps achieve stable compensation of vitamin D3 deficiency.

This publication has 29 references indexed in Scilit: